Transgenic mice bearing specific altered cellular oncogenes represent a powerful new approach for testing the efficacy of these genes as tumorigenic agents, for determining how a single oncogene alters cell populations within the animal, for analysing how different oncogenes interact in diverse cell types, for exploring the pre-neoplastic state, and for creating a ready source of novel tumor cell lines. Recently we have shown that the c-myc oncogene, when driven by immunoglobulin u or k enhances Eu or Ek), elicits malignant lymphoma and lymphoblastic leukemia in transgenic mice. We propose to define the pathogenesis of this heritable disease, to assess the genetic influence of the host background, and to characterize the tumors in order to define the susceptible cell types and their capacity for self renewal and differentiation. The pre-neoplastic state we have identified in the young Eu-myc transgenic mice will be explored by analysis of the perturbations in lymphoid and other hematopoietic populations in vivo and the behavior of myc-driven cells in culture (e.g. factor dependence, persistence, proliferation rate). To assess oncogene cooperativity in hematopoietic cells, we will attempt to transform these pre- leukemic cells in vitro as well as searching for further oncogenic alterations within the tumor cells that arise spontaneously in vivo. The promising start with Eu-myc mice encourages us to make analogous mice bearing other oncogenes implicated in various lymphoid and other hemopoietic malignancies, including different versions of the myb, ras and abl genes. These studies should help to delineate how these oncogenes influence differentiation within the various hemopoietic lineages and provide valuable animal models for the early stages of leukemogenesis.
| Campbell, Kirsteen J; Vandenberg, Cassandra J; Anstee, Natasha S et al. (2017) Mnt modulates Myc-driven lymphomagenesis. Cell Death Differ 24:2117-2126 |
| Anstee, Natasha S; Vandenberg, Cassandra J; Campbell, Kirsteen J et al. (2017) Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice. Cell Death Differ 24:397-408 |
| Vandenberg, C J; Motoyama, N; Cory, S (2016) FoxO3 suppresses Myc-driven lymphomagenesis. Cell Death Dis 6:e2046 |
| Vandenberg, Cassandra J; Waring, Paul; Strasser, Andreas et al. (2014) Plasmacytomagenesis in E?-v-abl transgenic mice is accelerated when apoptosis is restrained. Blood 124:1099-109 |
| Vandenberg, C J; Josefsson, E C; Campbell, K J et al. (2014) Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice. Cell Death Differ 21:676-84 |
| Vandenberg, Cassandra J; Cory, Suzanne (2013) ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121:2285-8 |
| Mason, Kylie D; Lin, Ann; Robb, Lorraine et al. (2013) Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proc Natl Acad Sci U S A 110:2599-604 |
| Kaufmann, T; Strasser, A; Jost, P J (2012) Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19:42-50 |
| Campbell, K J; Gray, D H D; Anstee, N et al. (2012) Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection. Cell Death Differ 19:1962-71 |
| Slape, Christopher I; Saw, Jesslyn; Jowett, Jeremy B M et al. (2012) Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. Blood 120:2475-83 |
Showing the most recent 10 out of 186 publications
